Last updated: September 15, 2026
Testosterone undecanoate is expanding from a niche long-acting injectable into a multi-product androgen-replacement market. Revenue growth is driven by oral products Jatenzo, Tlando and Kyzatrex, while Aveed and Bayer’s Nebido retain value through extended dosing intervals. The market remains constrained by cardiovascular, prostate, erythrocytosis and blood-pressure warnings, as well as competition from lower-cost testosterone cypionate, enanthate, gels and pellets.
The commercial outlook favors differentiated products with reliable absorption, less frequent dosing and strong prescriber support. The principal financial risk is substitution by inexpensive generic testosterone formulations rather than immediate patent expiry of testosterone undecanoate products.
What is the current testosterone undecanoate market structure?
Testosterone undecanoate is marketed in two main forms:
- Long-acting intramuscular injections, including Aveed in the United States and Nebido in many international markets.
- Oral softgel capsules, including Jatenzo, Tlando and Kyzatrex in the United States.
| Product |
Active ingredient |
Route |
Main company or commercial sponsor |
U.S. FDA status |
Commercial positioning |
| Aveed |
Testosterone undecanoate |
Intramuscular |
Endo Pharmaceuticals |
Approved 2014 |
Long-acting injection administered in a clinical setting |
| Jatenzo |
Testosterone undecanoate |
Oral capsule |
Tolmar, following Clarus acquisition |
Approved 2019 |
Oral testosterone replacement |
| Tlando |
Testosterone undecanoate |
Oral capsule |
Antares Pharma, later acquired by Halozyme |
Approved 2022 |
Oral product without the same titration model as Jatenzo |
| Kyzatrex |
Testosterone undecanoate |
Oral capsule |
Marius Pharmaceuticals |
Approved 2022 |
Oral product using a proprietary lipid formulation |
| Nebido |
Testosterone undecanoate |
Intramuscular |
Bayer and regional licensees |
Approved outside the U.S. |
Long-interval injectable, generally dosed every 10 to 14 weeks |
The products compete within the broader testosterone-replacement-therapy market, where testosterone cypionate and testosterone enanthate injections remain the lowest-cost alternatives. Topical gels, patches, pellets and nasal products add further competition.
How large is the testosterone replacement therapy market?
The addressable market includes men with confirmed hypogonadism caused by testicular or hypothalamic-pituitary dysfunction. Prescribing also reflects off-label or controversial use in men with age-related testosterone decline, although FDA labeling limits approved use to specific medical conditions.
Testosterone replacement is a mature category with high prescription volume but substantial price dispersion:
| Segment |
Relative cost position |
Commercial characteristics |
| Generic testosterone cypionate |
Lowest |
High volume, low price, self-injection |
| Generic testosterone enanthate |
Low |
Similar economics to cypionate |
| Topical gels |
Medium to high |
Convenience, transfer risk and variable absorption |
| Pellets |
High |
Long duration, procedural administration |
| Aveed/Nebido |
High |
Long dosing interval and clinic administration |
| Oral testosterone undecanoate |
High |
Convenience, formulation differentiation and monitoring |
Testosterone undecanoate products target patients who value oral administration or reduced injection frequency. Their commercial opportunity is therefore measured against convenience and adherence, not only against molecule-level efficacy.
What are the main revenue drivers for testosterone undecanoate?
Oral administration
Jatenzo, Tlando and Kyzatrex avoid injections and may improve acceptance among patients unwilling to self-inject. Oral treatment also allows endocrinologists and urologists to position therapy as a routine chronic medicine rather than a procedure.
The commercial limitation is food-dependent or formulation-dependent absorption. Testosterone undecanoate is highly lipophilic, and oral products require specialized delivery systems to improve absorption through the lymphatic pathway.
Long dosing intervals
Aveed and Nebido are administered at intervals materially longer than weekly or biweekly testosterone cypionate. The resulting value proposition includes:
- Fewer injections
- Reduced treatment burden
- More consistent testosterone exposure
- Administration by a health-care professional
- Potentially better persistence in selected patients
Aveed carries a boxed warning for serious pulmonary oil microembolism and anaphylaxis. It must be administered in a certified setting with post-injection observation under an FDA-mandated risk evaluation and mitigation strategy, which adds operational cost and restricts administration sites (FDA, 2024a).
Formulation differentiation
The oral products do not compete solely on the testosterone undecanoate molecule. Their intellectual-property value is concentrated in formulation, absorption enhancement, dosing regimens and pharmacokinetic control.
This creates a higher barrier to direct substitution by an ordinary testosterone-undecanoate capsule. It does not eliminate competition from other testosterone products.
What is the financial trajectory of Jatenzo, Tlando, Kyzatrex and Aveed?
Public reporting provides an incomplete but directionally clear picture. Oral products have expanded category visibility, while their commercial performance depends on payer coverage, patient acquisition and prescription persistence.
| Product |
Financial trajectory |
Principal commercial constraint |
| Aveed |
Established specialty-product revenue base |
REMS administration burden and competing injectables |
| Jatenzo |
Early commercial adoption followed by ownership transition |
Blood-pressure warning, titration requirements and payer access |
| Tlando |
Initial launch followed by integration into Halozyme’s commercial portfolio |
Differentiation against other oral products and reimbursement |
| Kyzatrex |
Launch-stage growth opportunity |
Limited commercial scale and competition from established therapies |
| Nebido |
Mature international revenue stream |
Regional pricing, reimbursement and established generic injectables |
Clarus Therapeutics commercialized Jatenzo after FDA approval in 2019. Tolmar acquired Clarus and its assets in 2023, giving Jatenzo access to a broader specialty-pharmaceutical infrastructure. The transaction reduced standalone-company financing risk but placed the product within a portfolio where sales execution and payer access remain critical.
Antares launched Tlando after FDA approval in 2022. Halozyme acquired Antares in 2023 for approximately $960 million, including assumed debt and other transaction considerations. Tlando therefore became part of a larger specialty and drug-delivery platform rather than remaining an independent commercial asset (Halozyme, 2023).
Marius launched Kyzatrex after its 2022 FDA approval. The company is privately held, and detailed product revenue is not reported publicly in the same manner as a public pharmaceutical company. Its financial trajectory depends on building a prescriber base against better-established oral and injectable products.
Aveed has a longer commercial history but faces a structural ceiling from its administration requirements. It is more exposed to clinic capacity, reimbursement for administration and specialty-distribution execution than oral products.
What FDA regulatory issues affect testosterone undecanoate sales?
All U.S. testosterone products are subject to significant labeling and monitoring requirements.
The FDA requires testosterone replacement to be used for men with documented medical conditions associated with testosterone deficiency. The agency has warned that testosterone products are not approved for routine treatment of age-related testosterone decline without an associated medical condition (FDA, 2015).
Key regulatory factors include:
- Hematocrit and hemoglobin monitoring because testosterone can cause erythrocytosis.
- Prostate evaluation and monitoring.
- Blood-pressure monitoring.
- Assessment of cardiovascular risk.
- Restrictions or precautions in men with certain prostate, breast, cardiac or thromboembolic conditions.
- Product-specific pharmacokinetic monitoring.
- Special administration controls for Aveed.
In 2025, the FDA removed the class-wide boxed warning regarding increased risk of major adverse cardiovascular outcomes after reviewing available evidence, but required labeling changes warning that testosterone products can increase blood pressure. The change reduces one prominent prescribing barrier while creating a continuing monitoring obligation (FDA, 2025).
For oral products, blood pressure and absorption characteristics remain commercially important. Physicians may prefer oral therapy for convenience but avoid it in patients with uncontrolled hypertension or complex cardiovascular risk.
What patents protect testosterone undecanoate products?
The core testosterone undecanoate molecule is old and cannot support broad, long-term exclusivity by itself. Commercial protection instead centers on product-specific technology.
Jatenzo patent protection
Jatenzo’s protection is associated with oral testosterone-undecanoate formulations, absorption technology, dosing and pharmacokinetic performance. Its value is concentrated in formulation and method claims rather than in the active ingredient.
Tlando patent protection
Tlando relies on proprietary oral delivery and dosing technology. The relevant estate is directed toward formulation architecture, administration and achieving therapeutic testosterone exposure. The commercial objective is to prevent an equivalent oral product from using the same delivery approach during the protected period.
Kyzatrex patent protection
Kyzatrex uses a proprietary oral formulation intended to improve absorption and reduce dependence on conventional oral testosterone-undecanoate limitations. Its patent position is primarily formulation-based, with additional potential protection for dosing and use.
Aveed and Nebido protection
The long-acting injectable products depend on formulation, depot behavior, manufacturing controls and product-specific regulatory approvals. Much of the original compound-level exclusivity has expired or is not commercially decisive. Manufacturing know-how, regulatory complexity and clinical-administration requirements remain practical barriers.
The FDA Orange Book is the controlling source for listed U.S. patents and regulatory exclusivity. Patent listings can change through amendments, litigation, delisting or expiration, so product-level conclusions should be based on the current Orange Book record rather than historical patent summaries (FDA, 2024b).
When does testosterone undecanoate lose exclusivity?
There is no single loss-of-exclusivity date for testosterone undecanoate. The relevant timing differs by product, patent family, formulation and jurisdiction.
| Exclusivity layer |
Expected commercial effect |
| Active-ingredient exclusivity |
Limited because testosterone undecanoate is an old molecule |
| Formulation patents |
Can delay equivalent oral products |
| Method-of-use patents |
May restrict labeled uses but often have narrower commercial value |
| Regulatory exclusivity |
Usually shorter than the life of formulation patents |
| Manufacturing know-how |
Can delay practical competition without creating absolute legal exclusivity |
| REMS and administration requirements |
Raise entry and commercialization costs for injectable competitors |
Generic entry risk is therefore asymmetric. A competitor can enter the testosterone-replacement market without copying testosterone undecanoate. Generic testosterone cypionate and enanthate already offer a lower-price alternative. Direct oral testosterone-undecanoate entry is more difficult because an applicant must demonstrate bioequivalence or otherwise satisfy FDA requirements for the relevant dosage form and formulation.
Are Paragraph IV challenges likely for oral testosterone undecanoate?
Paragraph IV risk exists mainly for Jatenzo, Tlando and Kyzatrex because each has listed formulation and use patents that can be challenged by an abbreviated new drug application applicant.
A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable or will not be infringed. If the patent holder sues within the statutory period, FDA approval can be delayed for up to 30 months, subject to statutory exceptions and litigation outcomes (FDA, 2024b).
The most likely challenge targets are:
- Formulation patents with broad composition claims.
- Dosing patents with limited clinical differentiation.
- Food-effect or absorption claims.
- Method-of-use claims that overlap with the full labeled indication.
- Patents that expire materially later than the original approval date.
The commercial impact depends on whether the challenger can launch at risk, settle for an agreed entry date or invalidate the key formulation claims. A single surviving formulation patent can preserve meaningful value even if narrower method-of-use claims are defeated.
What is the biosimilar risk for testosterone undecanoate?
Biosimilar risk is not relevant to testosterone undecanoate because it is a chemically synthesized small molecule, not a biologic. The relevant competitors are generic drugs, authorized generics, branded formulations and therapeutic substitutes.
The main substitution risks are:
- Generic testosterone cypionate
- Generic testosterone enanthate
- Compounded testosterone products
- Topical testosterone gels
- Testosterone pellets
- Long-acting testosterone formulations using other esters
Compounded products can create price and availability pressure but do not have the same FDA approval, manufacturing controls or evidence package as approved products.
Which companies are challenging testosterone undecanoate products?
Competition is fragmented rather than concentrated in one direct generic challenger.
| Competitor group |
Competitive effect |
| Generic injectable manufacturers |
Price pressure and payer substitution |
| Branded oral testosterone developers |
Direct differentiation on convenience and absorption |
| Gel manufacturers |
Noninvasive alternative with established prescribing |
| Pellet providers |
Long duration and procedure-based adherence |
| Compounding pharmacies |
Local price competition and customized dosing |
| International manufacturers |
Regional competition against Nebido and other injectables |
The strongest commercial challenge comes from generic injections because payers can require them before covering higher-priced branded oral products. Direct oral competition is strategically important but has not displaced the broader injectable market.
How does testosterone undecanoate compare with testosterone cypionate?
| Attribute |
Testosterone undecanoate |
Testosterone cypionate |
| Administration |
Oral or long-acting injection |
Usually intramuscular injection |
| Dosing frequency |
Daily oral or approximately 10-week injection intervals |
Often weekly to biweekly |
| Cost |
Higher |
Low when generic |
| Absorption |
Formulation-dependent orally; depot-dependent by injection |
Predictable injectable absorption |
| Payer position |
Often requires coverage justification |
Common first-line low-cost option |
| Patent value |
Formulation and delivery patents |
Limited molecule-level protection |
| Commercial advantage |
Convenience and differentiated exposure |
Price and clinical familiarity |
| Main weakness |
Cost, monitoring and formulation constraints |
Injection burden and peak-trough variation |
Testosterone undecanoate wins when convenience, dosing interval or oral administration justifies a premium. Testosterone cypionate wins when cost and prescriber familiarity dominate.
What litigation and settlement issues affect the market?
The most material litigation risk is expected around Orange Book-listed formulation and dosing patents for branded oral products. Litigation outcomes can alter entry timing, royalty obligations and settlement economics.
Potential settlement structures include:
- A licensed generic entry date before patent expiration.
- A royalty-bearing supply or license arrangement.
- A covenant not to sue for a defined product.
- An authorized-generic arrangement.
- Restrictions on formulation, dosage strength or launch channel.
Public litigation and settlement data should be evaluated product by product. A broad market conclusion that testosterone-undecanoate products are protected until a single date is inaccurate because each product has a separate patent estate and litigation record.
What geographic markets offer the most opportunity?
The United States offers the highest concentration of differentiated oral-product value because it supports premium specialty pricing and has multiple FDA-approved oral products.
Europe and other international markets are more established around Nebido and long-acting injectable use. Commercial growth is influenced by:
- National reimbursement decisions.
- Tender pricing.
- Specialist prescribing.
- Local testosterone guidelines.
- Generic injectable availability.
- Distribution arrangements with Bayer and regional partners.
The United States is the primary market for new oral formulation launches. International expansion is more likely to rely on licensing, regional commercialization partners and local regulatory submissions than on direct global launches by smaller developers.
How strong is the testosterone undecanoate patent estate?
The estate is moderate for differentiated formulations and weak for the active ingredient itself.
| Patent category |
Relative strength |
| Testosterone undecanoate composition claims |
Low |
| Oral absorption formulation claims |
Moderate to strong |
| Dosing and pharmacokinetic claims |
Moderate |
| Method-of-use claims |
Moderate to weak |
| Injectable depot formulation claims |
Moderate |
| Manufacturing process claims |
Variable |
| Regulatory exclusivity |
Short to moderate |
Patent strength depends on claim breadth, written-description support, prosecution history, prior-art exposure and the ability to prove infringement through product testing. Formulation claims are commercially more important than method-of-use claims because they can block a competing product across the full indication.
What generic launch scenarios exist?
Three launch scenarios are commercially relevant:
Scenario 1: Injectable substitution continues
Generic testosterone cypionate and enanthate retain most high-volume prescribing. Testosterone undecanoate products grow in patients who prioritize convenience, longer intervals or oral administration.
Scenario 2: Oral products establish a premium segment
Jatenzo, Tlando and Kyzatrex gain coverage and compete for newly diagnosed or injection-averse patients. The oral segment becomes a meaningful specialty market, but not a replacement for generic injections.
Scenario 3: Direct oral generic entry
A successful Paragraph IV challenger enters after invalidating or licensing around key patents. Net pricing falls, branded promotional spending increases and the first product with the strongest surviving formulation patents captures share.
The most probable market structure is coexistence: low-cost injectable generics at the base, branded oral products in a premium segment and long-acting injections for selected patients and clinic-based administration.
Key Takeaways
- Testosterone undecanoate has moved from a primarily injectable product class to a multi-product market with three U.S. oral products.
- Jatenzo, Tlando and Kyzatrex rely mainly on formulation, absorption and dosing patents, not new-molecule protection.
- Aveed and Nebido retain value through long dosing intervals but face administration and monitoring burdens.
- Generic testosterone cypionate and enanthate are the largest commercial threat because they offer substantially lower prices.
- Biosimilar risk does not apply; generic and therapeutic-substitution risk does.
- FDA blood-pressure labeling and monitoring requirements remain important commercial constraints.
- Halozyme’s acquisition of Antares and Tolmar’s acquisition of Clarus changed the ownership and commercialization landscape.
- The strongest intellectual-property positions are likely to be formulation claims that block equivalent oral delivery systems.
- Generic entry will probably be product-specific and patent-specific rather than determined by one market-wide expiration date.
- Revenue growth depends on payer coverage, patient persistence and the ability to justify premium pricing against established injectable generics.
FAQs
Is testosterone undecanoate a biologic drug?
No. Testosterone undecanoate is a chemically synthesized small molecule. Generic-drug rules apply, and biosimilar regulation does not.
Which testosterone-undecanoate product lasts the longest?
Aveed and Nebido are long-acting injectable products generally administered at intervals of roughly 10 to 14 weeks, depending on the product label and patient schedule. Oral products require daily administration.
Does testosterone undecanoate require a REMS?
Aveed is subject to an FDA REMS because of the risk of pulmonary oil microembolism and anaphylaxis. The oral products do not have the same injection-site administration requirement.
Can a generic company copy Jatenzo by using testosterone undecanoate?
A generic applicant must address the listed formulation and use patents and satisfy FDA requirements for the relevant dosage form. Copying the active ingredient alone does not guarantee approval or freedom to launch.
Which product has the strongest commercial advantage?
The answer depends on the payer and patient segment. Generic testosterone cypionate has the strongest cost advantage, while oral testosterone undecanoate has the strongest convenience advantage. Long-acting injectable products have the clearest dosing-interval advantage.
References
-
U.S. Food and Drug Administration. (2014). FDA approves Aveed to treat men with low testosterone. FDA.
-
U.S. Food and Drug Administration. (2015). FDA drug safety communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke. FDA.
-
U.S. Food and Drug Administration. (2019). Jatenzo prescribing information. FDA.
-
U.S. Food and Drug Administration. (2022a). Tlando prescribing information. FDA.
-
U.S. Food and Drug Administration. (2022b). Kyzatrex prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024a). Aveed prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2025). FDA issues labeling changes for testosterone products regarding blood pressure. FDA.
-
Halozyme Therapeutics, Inc. (2023). Halozyme completes acquisition of Antares Pharma. Company release.
-
Bayer AG. (2023). Nebido product information. Bayer.
